Recursion: Breakthrough in Drug Development

This is a news story, published by Yahoo Finance, that relates primarily to Recursion Pharmaceuticals news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Recursion Pharmaceuticals

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biotech news, stocks news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

risky stock

The Motley Fool

•

Health

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?

Summary

Nutrition label

74% Informative

Recursion Pharmaceuticals (NASDAQ: RXRX) could help revolutionize the way drugs are developed.

The biotech company has developed an AI-powered operating system (OS) that features a library of human genes.

This OS is constantly testing clinical compounds against this library.

The potential benefits here could be faster discovery, faster development, lower costs, longer time spent under patent exclusivity on the market, higher sales, higher profits, and higher margins.

Yet, the company has yet to prove itself and remains a risky stock.

Stock Advisor’s total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500.

If you invested $ 1,000 at the time of our recommendation, you’d have $ 870,207 ! Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful